Skip to main content
. 2020 Apr 28;10:7162. doi: 10.1038/s41598-020-64195-x

Figure 3.

Figure 3

Effects of Ramucirumab and/or Paclitaxel on cell cycle progression in gastric cancer cell lines. (a) AGS, NCI-N87 [N87], HGC-27 and KATO III human gastric cancer cells were synchronized in the G2/M phase of the cell cycle (T0). 1 nM Paclitaxel and 100 μg/ml Ram alone or in combination were administrated to a subgroup of cells processed after 3 h from block release (T1). The percentage of cells in the subsequent G0/G1 phase was evaluated and plotted in the graphs. The results of three independent experiments, expressed as mean ± SD, were plotted in the relative graphs. *p < 0.05; **p < 0.001; ***p < 0.0001. (b) The expression of activated cdc25A, cdc2, Cyclin B1, c-myc and STAT3 was analyzed in AGS and KATO III cells after 48 h of Ram and/or PTX treatment. Three independent experiments were performed and a representative Western Blotting image is shown.